Trimodality Therapy in Bladder Cancer Who, What, and When?

被引:29
|
作者
Premo, Christopher [1 ]
Apolo, Andrea B. [2 ]
Agarwal, Piyush K. [3 ]
Citrin, Deborah E. [1 ]
机构
[1] NIH, Radiat Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA
[2] NCI, Bladder Canc Sect, Genitourinary Malignancies Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
[3] NCI, Bladder Canc Sect, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
TRANSITIONAL-CELL-CARCINOMA; COMBINED-MODALITY THERAPY; LONG-TERM OUTCOMES; SELECTIVE ORGAN PRESERVATION; GROWTH-FACTOR RECEPTOR; QUALITY-OF-LIFE; RADIATION-THERAPY; TRANSURETHRAL RESECTION; RADICAL RADIOTHERAPY; NEOADJUVANT CHEMOTHERAPY;
D O I
10.1016/j.ucl.2015.02.002
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Radical cystectomy is a standard treatment of nonmetastatic, muscle-invasive bladder cancer. Treatment with trimodality therapy consisting of maximal transurethral resection of the bladder tumor followed by concurrent chemotherapy and radiation has emerged as a method to preserve the native bladder in highly motivated patients. Several factors can affect the likelihood of long-term bladder preservation after trimodality therapy and therefore should be taken into account when selecting patients. New radiation techniques such as intensity modulated radiation therapy and image-guided radiation therapy may decrease the toxicity of radiotherapy in this setting. Novel chemotherapy regimens may improve response rates and minimize toxicity.
引用
收藏
页码:169 / +
页数:13
相关论文
共 50 条
  • [31] Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions
    Jiang, Di Maria
    Chung, Peter
    Kulkarni, Girish S.
    Sridhar, Srikala S.
    CURRENT ONCOLOGY REPORTS, 2020, 22 (02)
  • [32] Subtyping Muscle-Invasive Bladder Cancer to Assess Clinical Response to Trimodality Therapy
    Efstathiou, J. A.
    Gibb, E.
    Miyamoto, D. T.
    Wu, C. L.
    Drumm, M. R.
    Lehrer, J.
    Ashab, H. A. D. M.
    Erho, N. G.
    du Plessis, M.
    Ong, K.
    Bhat, A.
    Mouw, K.
    Davicioni, E.
    Shipley, W. U.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : S118 - S118
  • [33] Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival
    Tang, Yaxiong
    Lin, Lede
    Xiao, Yunfei
    Meng, Linghao
    Yang, Yujia
    Li, Xiang
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (02): : 446 - 455
  • [34] Genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy.
    Miyamoto, David Tomoaki
    Gibb, Ewan
    Mouw, Kent William
    Liu, Yang
    Wu, Chin-Lee
    Drumm, Michael
    Lehrer, Jonathan
    Ashab, Hussam Al-Deen
    Erho, Nicholas
    Du Plessis, Marguerite
    Ong, Kaye
    Shipley, William U.
    Davicioni, Elai
    Efstathiou, Jason A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [35] Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival
    Yaxiong Tang
    Lede Lin
    Yunfei Xiao
    Linghao Meng
    Yujia Yang
    Xiang Li
    Clinical and Translational Oncology, 2024, 26 : 446 - 455
  • [36] Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions
    Di Maria Jiang
    Peter Chung
    Girish S. Kulkarni
    Srikala S. Sridhar
    Current Oncology Reports, 2020, 22
  • [37] Bladder preservation with trimodality therapy. Is it really necessary?
    Angulo, J.
    ACTAS UROLOGICAS ESPANOLAS, 2010, 34 (09): : 745 - 748
  • [38] Radical trimodality therapy for patients with locally advanced bladder cancer: The British Columbia Cancer Agency experience
    Baxter, Emily
    Dennis, Kristopher
    Kollmannsberger, Christian
    Black, Peter
    Attwell, Andrew
    Morris, William J.
    Tyldesley, Scott
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (02) : 66.e13 - 66.e19
  • [39] Cardiac Resynchronization Therapy: What? Who? When? How?
    Cuculich, Phillip S.
    Joseph, Susan
    AMERICAN JOURNAL OF MEDICINE, 2011, 124 (09): : 813 - 815
  • [40] Nomogram for Predicting Risk of Cystectomy or Recurrence after Bladder Preserving Trimodality Therapy for Muscle Invasive Bladder Cancer
    Coen, J.
    Paly, J. J.
    Efstathiou, J. A.
    Niemierko, A.
    Kaufman, D. S.
    Heney, N. M.
    Spiegel, D. Y.
    Zietman, A. L.
    Shipley, W. U.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S71 - S71